Comment on the article: In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model
This article comments on a paper published by Igarashi et al. (Pharm Res. 2023;40(7):1789–97), which describes an animal model for determining the optimal pharmacokinetic/pharmacodynamic (PK/PD) value for cefditoren against Streptococcus pneumoniae, to be used as a target parameter in a subsequent p...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Recursos: | Universidad Europea (UEM) |
| Repositorio: | ABACUS. Repositorio de Producción Científica |
| Idioma: | inglés |
| OAI Identifier: | oai:abacus.universidadeuropea.com:11268/13280 |
| Acesso em linha: | http://hdl.handle.net/11268/13280 |
| Access Level: | acceso abierto |
| Palavra-chave: | Streptococcus pneumoniae Antibacterianos Bacteria Farmacología Goal 3: Ensure healthy lives and promote well-being for all at all ages Goal 10: Reduce inequality within and among countries |
| Resumo: | This article comments on a paper published by Igarashi et al. (Pharm Res. 2023;40(7):1789–97), which describes an animal model for determining the optimal pharmacokinetic/pharmacodynamic (PK/PD) value for cefditoren against Streptococcus pneumoniae, to be used as a target parameter in a subsequent population pharmacokinetic analysis. |
|---|